July 11, 2016
Learn more by reading a recent blog by Marlana Orloff, MD, Assistant Professor of Medical Oncology at Sidney Kimmel Medical College and researcher at Sidney Kimmel Cancer Center. “Success in melanoma has propelled the use of these drugs into many other cancers including lung, kidney, breast, pancreatic, leukemias, lymphomas, and brain, most of which remain in clinical trials,” said Dr. Orloff.
Assistant Professor of Medical Oncology and researcher at Sidney Kimmel Cancer Center at Jefferson, recently wrote a blog for Philly.com regarding the promise and issues with immunotherapy.
“Given that a decade ago, very few people survived metastatic melanoma long term, these drugs are nothing short of miraculous for some,” said Dr. Orloff.
In her blog, Dr. Orloff discusses some factors related to immunotherapy including side effects, cost and individual patient reactions to the treatments. She notes two of her patient cases where she used immunotherapy for melanoma, but with different results.
“Immunotherapy in melanoma has ignited a scientific revolution and has offered the promise of a cure,” said Dr. Orloff. “There are dozens of clinical trials posing questions that could help reduce side effects and investigating new types of immunotherapies. Success in melanoma has propelled the use of these drugs into many other cancers including lung, kidney, breast, pancreatic, leukemias, lymphomas, and brain, most of which remain in clinical trials.”
Dr. Orloff also notes in the blog the fact that immunotherapy agents have been FDA approved for both Hodgkin’s lymphoma and bladder cancer.
See the blog on Philly.com and learn about this and other Jefferson news developments on the @Jeff news blog.
Weblink (Click Here)